Open AccessJournal Article
Gelatin-Based Plasma Expander Effectively Reduces Renal Uptake of 111In-Octreotide in Mice and Rats
Julliëtte E.M. van Eerd,Erik Vegt,Jack F.M. Wetzels,Frans G. M. Russel,Rosalinde Masereeuw,Frans H.M. Corstens,Wim J.G. Oyen,Otto C. Boerman +7 more
Reads0
Chats0
TLDR
Gelofusine is a well-known and generally used blood volume substitute that can be applied safely without the induction of toxicity, and evaluation of this compound for its potential to reduce the kidney uptake of radiolabeled peptides in patients is warranted.Abstract:
111In-Diethylenetriaminepentaacetic acid-octreotide generally is used for the scintigraphic imaging of neuroendocrine and other somatostatin receptor–positive tumors. On the basis of the successful targeting of octreotide, radiolabeled somatostatin analogs, such as 90Y-(1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid [DOTA])0-Tyr3-octreotide and 177Lu-DOTA0-Tyr3-octreotate, were developed for peptide receptor radionuclide therapy. However, the maximum tolerated doses of these analogs are limited because of the high and persistent renal uptake that leads to relatively high radiation doses in the kidneys. Renal uptake can be reduced by coinfusion of basic amino acids or polypeptides. However, high doses of basic amino acids can induce severe side effects. It was reported that the infusion of gelatin-based plasma expanders resulted in increased low-molecular-weight proteinuria, suggesting that these plasma expanders interfere with the tubular reabsorption of peptides and proteins. In the present study, we analyzed the effects of several plasma expanders on the renal uptake of 111In-octreotide in rats and mice. Methods: Wistar rats and BALB/c mice were injected with 0.5 or 0.1 mL of plasma expander, respectively. Thereafter, the animals received 111In-octreotide intravenously. Animals were killed at 20 h after the injection of the radiopharmaceutical. Organs were dissected, and the amount of radioactivity in the organs and tissues was measured. Results: The administration of 20 mg of Gelofusine in rats or 4 mg in mice was as effective in reducing the renal uptake of 111In-octreotide as the administration of 80 or 20 mg of lysine in rats or mice, respectively, without reducing 111In-octreotide uptake in receptor-positive organs. Plasma expanders based on starch or dextran had no effect on the renal uptake of 111In-octreotide. Conclusion: The gelatin-based plasma expander Gelofusine significantly reduced the kidney uptake of 111In-octreotide as effectively as did lysine. Because Gelofusine is a well-known and generally used blood volume substitute that can be applied safely without the induction of toxicity, evaluation of this compound for its potential to reduce the kidney uptake of radiolabeled peptides in patients is warranted.read more
Citations
More filters
Journal ArticleDOI
Use and application of gelatin as potential biodegradable packaging materials for food products.
TL;DR: This review will present the current situation with respect to gelatin usage as a packaging source material and the challenges that remain in order to move the manufacture of gelatin-based films nearer to commercial reality.
Journal ArticleDOI
Radiolabeled peptides: valuable tools for the detection and treatment of cancer.
TL;DR: Recent developments in the field of small peptides, and their applications in the diagnosis and treatment of cancer are presented.
Journal ArticleDOI
Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
Erik Vegt,Marion de Jong,Jack F.M. Wetzels,Rosalinde Masereeuw,Marleen Melis,Wim J.G. Oyen,Martin Gotthardt,Otto C. Boerman +7 more
TL;DR: An overview of renal handling of radiolabeled peptides and resulting nephrotoxicity is presented, and strategies to reduce neph rotoxicity are discussed.
Journal ArticleDOI
64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression
TL;DR: Polyvalency has a profound effect on the receptor-binding affinity and in vivo kinetics of radiolabeled RGD multimers, as compared with the other RGD analogs.
Journal ArticleDOI
Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
Anna Orlova,Vladimir Tolmachev,Rikard Pehrson,Malin Lindborg,Thuy A Tran,Mattias Sandström,Fredrik Y. Nilsson,Anders Wennborg,Lars Abrahmsén,Joachim Feldwisch +9 more
TL;DR: The present results show that radiolabeled synthetic DOTA-Z(HER2:342-pep2) has the potential to become a clinically useful radiopharmaceutical for in vivo molecular imaging of HER2-expressing carcinomas.
References
More filters
Journal ArticleDOI
Collagen fibril formation
TL;DR: Preliminary evidence from invertebrates is included which suggests that the principles for bipolar fibril assembly were established at least 500 million years ago, and how mature fibrils are assembled from early fibrILS is reviewed.
Journal ArticleDOI
Megalin and cubilin: multifunctional endocytic receptors
TL;DR: The ability to take up substances from the surrounding environment not only provides cells with vital nutrients, but also enables the selective transport of substances from one compartment to another.
Journal ArticleDOI
Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.
Søren K. Moestrup,Shiying Cui,Henrik Vorum,C. Bregengard,Søren E. Bjørn,K. Norris,Jørgen Gliemann,E I Christensen +7 more
TL;DR: A novel role of gp330 as a drug receptor is demonstrated and the new insight into the mechanism of epithelial uptake of polybasic drugs might provide a basis for future design of drugs with reduced toxicity.
Journal ArticleDOI
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
TL;DR: It is concluded that co-infusion of Lys75 or LysArg results in a significant inhibition of renal radioactivity in PRRT, allowing higher treatment doses and thus resulting in higher tumour radiation doses.
Journal Article
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Roelf Valkema,Stanislas Pauwels,Larry K. Kvols,Dik J. Kwekkeboom,François Jamar,Marion de Jong,Raffaella Barone,Stephan Walrand,P. P. M. Kooij,Willem H. Bakker,Janet Lasher,Eric P. Krenning +11 more
TL;DR: The time course of CLR after PRRT was compatible with the pattern of sustained CLR loss in progressive chronic kidney disease, and the time trend of decline in CLR was sustained during the follow-up period.